Study Comparing Pembrolizumab With Dual MAPK Pathway Inhibition Plus Pembrolizumab in Melanoma Patients
Status:
Unknown status
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2 trial consisting of 24 patients receiving the combination of dabrafenib +
trametinib + pembrolizumab in 3 different dosing schemes and 8 patients receiving
pembrolizumab standard monotherapy. All patients start with pembrolizumab standard therapy
for 6 weeks and will then be randomized to continue pembrolizumab monotherapy or to receive
additional intermitted/short-term dabrafenib + trametinib.
Stratification will be baseline LDH level and baseline PD-L1 expression.